Clinical Trial Update: Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial assessing first-line Bevacizumab (Avastin) plus Erlotinib for stage IIIB/IV or recurrent non-squamous non-small cell lung cancer. Results were p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Avastin (bevacizumab)
• Tarceva (erlotinib)

Snippet

Sponsor: University of Utah | Conditions: Cancer | Phase 2 | Status: COMPLETED | Results posted: 2015-09-24